Načítá se...
Ofatumumab for the Treatment of Childhood Nephrotic Syndrome
BACKGROUND: Ofatumumab is a humanized anti-CD20 monoclonal antibody that has recently garnered interest as a potential therapeutic agent for nephrotic syndrome. We report our center's experience in administering ofatumumab to 5 pediatric patients with idiopathic nephrotic syndrome. METHODS: Bet...
Uloženo v:
| Vydáno v: | Pediatr Nephrol |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5373940/ https://ncbi.nlm.nih.gov/pubmed/28213687 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00467-017-3621-8 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|